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Abstract
Background: Many neglected tropical infectious diseases affecting humans are transmitted by arthropods such as
mosquitoes and ticks. New mode-of-action chemistries are urgently sought to enhance vector management practices in
countries where arthropod-borne diseases are endemic, especially where vector populations have acquired widespread
resistance to insecticides.
Methodology/Principal Findings: We describe a ‘‘genome-to-lead’’ approach for insecticide discovery that incorporates the
first reported chemical screen of a G protein-coupled receptor (GPCR) mined from a mosquito genome. A combination of
molecular and pharmacological studies was used to functionally characterize two dopamine receptors (AaDOP1 and
AaDOP2) from the yellow fever mosquito, Aedes aegypti. Sequence analyses indicated that these receptors are orthologous
to arthropod D1-like (Gas-coupled) receptors, but share less than 55% amino acid identity in conserved domains with
mammalian dopamine receptors. Heterologous expression of AaDOP1 and AaDOP2 in HEK293 cells revealed dose-
dependent responses to dopamine (EC50: AaDOP1=3.161.1 nM; AaDOP2=240616 nM). Interestingly, only AaDOP1
exhibited sensitivity to epinephrine (EC50=5.861.5 nM) and norepinephrine (EC50=7606180 nM), while neither receptor
was activated by other biogenic amines tested. Differential responses were observed between these receptors regarding
their sensitivity to dopamine agonists and antagonists, level of maximal stimulation, and constitutive activity. Subsequently,
a chemical library screen was implemented to discover lead chemistries active at AaDOP2. Fifty-one compounds were
identified as ‘‘hits,’’ and follow-up validation assays confirmed the antagonistic effect of selected compounds at AaDOP2. In
vitro comparison studies between AaDOP2 and the human D1 dopamine receptor (hD1) revealed markedly different
pharmacological profiles and identified amitriptyline and doxepin as AaDOP2-selective compounds. In subsequent Ae.
aegypti larval bioassays, significant mortality was observed for amitriptyline (93%) and doxepin (72%), confirming these
chemistries as ‘‘leads’’ for insecticide discovery.
Conclusions/Significance: This research provides a ‘‘proof-of-concept’’ for a novel approach toward insecticide discovery, in
which genome sequence data are utilized for functional characterization and chemical compound screening of GPCRs. We
provide a pipeline useful for future prioritization, pharmacological characterization, and expanded chemical screening of
additional GPCRs in disease-vector arthropods. The differential molecular and pharmacological properties of the mosquito
dopamine receptors highlight the potential for the identification of target-specific chemistries for vector-borne disease
management, and we report the first study to identify dopamine receptor antagonists with in vivo toxicity toward
mosquitoes.
Citation: Meyer JM, Ejendal KFK, Avramova LV, Garland-Kuntz EE, Giraldo-Caldero ´n GI, et al. (2012) A ‘‘Genome-to-Lead’’ Approach for Insecticide Discovery:
Pharmacological Characterization and Screening of Aedes aegypti D1-like Dopamine Receptors. PLoS Negl Trop Dis 6(1): e1478. doi:10.1371/journal.pntd.0001478
Editor: Rhoel Ramos Dinglasan, Johns Hopkins Bloomberg School of Public Health, United States of America
Received July 15, 2011; Accepted November 29, 2011; Published January 24, 2012
Copyright:  2012 Meyer et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This research was supported by a Purdue University, Discovery Park Seed Grant (#203606) and a Department of Defense/TATRC sub-award (#201596-
PU) to C.A.H. and V.J.W. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: hillca@purdue.edu
. These authors contributed equally to this work.
Introduction
Mosquitoes (Class Insecta; Order Diptera; Family Culicidae)
vector multiple neglected tropical diseases (NTDs) affecting
human health, including malaria, yellow-fever, dengue and
filariasis. Historically, insecticides employed against arthropod
disease vectors have reduced the impact of NTDs, but unfortu-
nately, continued disease control is threatened by the widespread
development of vector populations that are resistant to insecticidal
chemistries [1]. This issue is further complicated by the fact that
www.plosntds.org 1 January 2012 | Volume 6 | Issue 1 | e1478there has not been a new public health insecticide produced for
vector-borne disease control for over 30 years [2]. Recently,
philanthropic investment has focused attention toward the
development of new drugs to control NTDs in the human
population [3]. It is widely recognized that an arsenal of new
vector control solutions are required in order to meet this and
other public health goals regarding NTDs. Thus, the research
community should aggressively pursue the discovery of new mode-
of-action chemistries for mosquito control through both traditional
phenotypic screening and target-based approaches.
Novel insecticide targets potentially exist among the arthropod
G protein-coupled receptors (GPCRs). These proteins comprise a
large family of membrane-bound molecules that mediate critical
biological processes such as neurotransmission, vision, and
hormonal regulation, among others [4,5]. GPCRs are extensively
targeted for drug development in humans - approximately 40% of
prescription pharmaceuticals interact with these receptors [6] -
and more recently, Gamo et al. [7] reported multiple GPCR-
interacting chemistries as promising anti-malarial leads. Also, the
mode-of-action of amitraz, a chemistry registered for tick and
insect control, is presumed to have partial agonistic activity at an
octopamine sensitive GPCR [8]. More than 100 different GPCRs
have been identified in the genomes of multiple insect species,
including malaria- and yellow fever-transmitting mosquitoes
[9,10]. These studies have provided a basis for the functional
characterization of GPCRs and their prioritization as potential
subjects for insecticide development.
The biogenic amine-binding GPCRs (rhodopsin-like) are integral
components of the central and peripheral nervous systems of
eukaryotes and include receptors that bind the neurotransmitters
dopamine, histamine, octopamine, serotonin, tyramine, and
acetylcholine [11]. The dopamine receptors are classified as either
D1-o rD 2-like [12] based on their differential functional roles.
Ligand binding to the D1-like dopamine receptors causes Gas-
mediated stimulation of adenylyl cyclase (AC) production of cAMP.
A reciprocal effect is observed following agonist activation of D2-like
dopamine receptors, whereby cAMP production by AC is inhibited
via Gai/o proteins. Dopamine and its receptors are essential for
complex behavioral mechanisms in arthropods such as locomotion
[13,14,15], arousal [16], and olfactory learning [17,18].
The importance of dopaminergic-related functions has stimu-
lated research to understand these processes in mosquitoes.
Dopamine and serotonin have been tied to salivary gland
functioning of vectors [19,20] and may have an impact on
pathogen acquisition and transmission during blood feeding.
Andersen et al. [21] reported that increased levels of dopamine
were detected in Aedes aegypti following a blood meal that were
implicated in ovarian or egg development, and in newly-emerged
adults, presumably as part of the sclerotization process. Much
attention has been given to the role of dopamine in the
melanization pathway of mosquitoes and other insects, as well as
the effect of dopamine on development, pigmentation, reproduc-
tion, immune responses to parasites, wound healing, and Wolbachia
infection [22,23,24,25,26,27]. In the mosquito Culex pipiens, dose-
dependent increases in cAMP were detected following treatment
with dopamine and octopamine in homogenized head tissues,
suggesting the presence of Gas-coupled receptors that are
responsive to these biogenic amines [28]. Putative D1-like and
D2-like dopamine receptors have been identified in the genomes of
the mosquitoes Ae. aegypti [9] and Anopheles gambiae [10], but
research investigating their pharmacological properties is lacking.
These genomic sequences provide a logical starting point to
functionally characterize the receptors, which is needed to
improve our comprehension of dopaminergic processes in
mosquitoes. Moreover, due to their presumed significance in
mosquito neurobiology, these dopamine receptors are attractive
candidates to explore as new targets for chemical control.
We present the results of a ‘‘proof-of-concept’’ study involving a
‘‘genome-to-lead’’ approach for developing new mode-of-action
insecticides for arthropod disease vectors (Figure 1A). Our
research strategy involves (i) exploitation of an arthropod genome
sequence for novel target identification, (ii) molecular, biochemical
and pharmacological target validation, (iii) chemical library
screening, and (iv) confirmation of hits and identification of
candidate ‘‘leads’’ using secondary in vitro assays and mosquito in
vivo assays. Toward these objectives, two dopamine receptors
(AaDOP1 and AaDOP2) were identified in the genome of the
yellow-fever mosquito, Ae. aegypti, and characterized using
molecular and pharmacological methods. Subsequently, we
conducted a chemical library screen in which multiple lead
antagonistic chemistries of the AaDOP2 receptor were identified.
Finally, we employed a ‘‘hit-to-lead’’ approach (Figure 1B),
wherein screen ‘‘hits’’ were confirmed in secondary in vitro assays
and two ‘‘lead’’ chemistries were identified using in vivo assays that
confirmed their toxicity to mosquito larvae. These results serve as
an entry point for expanded chemical library screening of
mosquito dopamine receptors and subsequent structure-activity
relationship- and further ‘‘hit-to-lead’’-studies to discover candi-
date compounds that will enter the registration phase of product
development (Figure 1A). Our pipeline will expedite the
exploration of GPCRs as potential targets for chemical control
in mosquitoes and other important arthropod disease vectors for
which sufficient genome sequence data is available.
Materials and Methods
Molecular analyses
The gene sequences for the putative dopamine receptors
AaegGPRdop1 (AAEL003920) and AaegGPRdop2 (AAEL005834)
Author Summary
Mosquitoes and other arthropods transmit important
disease-causing agents affecting human health worldwide.
There is an urgent need to discover new chemistries to
control these pests in order to reduce or eliminate
arthropod-borne diseases. We describe an approach to
identify and evaluate potential insecticide targets using
publicly available genome (DNA) sequence information for
arthropod disease vectors. We demonstrate the utility of
this approach by first determining the molecular and
pharmacological properties of two different dopamine
(neurotransmitter) receptors of the yellow fever- and
dengue-transmitting mosquito, Aedes aegypti. Next, we
tested 1,280 different chemistries for their ability to
interact with one of these dopamine receptors in a
chemical screen, and 51 ‘‘hit’’ compounds were identified.
Finally, we show that two of these chemistries, amitripty-
line and doxepin, are selective for the mosquito over the
human dopamine receptor and that both chemistries
caused significant mortality in mosquito larvae 24 hours
after exposure, identifying them as possible ‘‘leads’’ for
insecticide development. Our methodology is adaptable
for chemical screening of related targets in mosquitoes
and other arthropod vectors of disease. This research
demonstrates the potential of target-specific approaches
that could complement traditional phenotypic screening,
and ultimately may accelerate discovery of new mode-of-
action insecticides for vector control.
D1-like Dopamine Receptors in Aedes aegypti
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[10] were downloaded from VectorBase (http://www.vectorbase.
org/index.php) [29]. Sequences of the D1-like dopamine receptors
in Drosophila melanogaster were used to identify and compare
conserved structural features [30,31].
Gene expression analyses for each receptor were conducted
using RNA extracted from the eggs, larvae, pupae, and adult male
and female mosquitoes from the Liverpool strain of Ae. aegypti [10].
Total RNA was isolated using TRIzol Reagent (Invitrogen,
Carlsbad, CA) and then treated with RNase-Free DNase
(QIAGEN, Valencia, CA). The SuperScript One-Step RT-PCR
kit (Invitrogen, Carlsbad, CA) was used to amplify receptor
mRNA from approximately 150 ng total RNA per reaction using
the primers and experimental conditions provided in Table S1.
RT-PCR amplification products were electrophoresed and
compared by size to the DNA HyperLadder I (Bioline USA
Inc., Randolph, MA). Products were cut from the gel and isolated
with the Qiagen Gel Extraction Kit (Qiagen Valencia, CA). The
cloning procedure was performed using the TOPO TA cloning kit
(Invitrogen, Carlsbad, CA), according to the manufacturer’s
instructions. DNA sequencing was conducted at the Purdue
University Genomics Core Facility. The resultant DNA sequences
were used to predict full-length coding regions that were manually
annotated using Artemis software (version 9) [32].
A neighbor-joining sequence analysis was performed using the
deduced amino acid sequences representing the mosquito
dopamine receptor proteins (referred to hereafter as AaDOP1
and AaDOP2), additional representative biogenic amine recep-
tors from the insects D. melanogaster and A. mellifera,a n dt h e
human D1- and D2-like dopamine receptors. ClustalW 1.83 [33]
was used for sequence alignments prior to tree construction in
PAUP 4.0b4a [34]. The bootstrap method (100 replicates) was
used to provide branch support. Alignments of amino acid
sequences for determination of conserved motifs were conducted
using Multalin software [35]. Conserved amino acid residues and
additional protein features were predicted as described by Meyer
et al. [36].
Heterologous expression
Functional characterization of AaDOP1 and AaDOP2 was
conducted by heterologous expression in HEK293 cells (ATCC,
Manassas, VA) [36]. Expression constructs were produced by
synthesis (GenScript, Piscataway, NJ) and included the partial
Kozak transcriptional recognition sequence ‘‘CACC’’ added
directly upstream of the transcription initiation codon for each
gene. Constructs were cloned into pUC57 and then subcloned into
the expression vector pcDNA3.1+ (Invitrogen, Carlsbad, CA) by
GenScript (Piscataway, NJ). Stable cell lines co-expressing either
AaDOP1 or AaDOP2 with a CRELuc reporter construct were
developed to permit pharmacological studies in a 384-well format
[36,37]. Briefly, cells already stably expressing the CRELuc
reporter construct were transfected in a 10 cm dish with 15 ml
Lipofectamine2000 and 3 mg of pcDNA3.1+/Aadop1 or
pcDNA3.1+/Aadop2. Clones were maintained as described for
the wild-type HEK293 cells [36] with the addition of 2 mg/ml
puromycin and 300 mg/ml Geneticin (Sigma-Aldrich, St. Louis,
MO).
Pharmacological characterization
For initial functional analysis, the receptors were transiently
expressed in HEK293 cells [36] and analyzed using a competitive
binding assay to measure levels of cAMP accumulation [37]. Dose-
response curves were generated using cells stably expressing the
receptors [36,37]. The compounds used for pharmacological
characterization included dopamine hydrochloride, histamine
dihydrochloride, 5-hydroxytryptamine hydrochloride (serotonin),
(6)-octopamine hydrochloride, tyramine hydrochloride (Sigma-
Aldrich, St. Louis, MO), (2)-epinephrine bitartrate, and L (2)-
norepinephrine bitartrate (Research Biochemical International,
Natick, MA). The synthetic dopamine receptor ligands tested
included SKF38393 and SKF81297 (Tocris, Ellisville, MO),
SCH23390 (Tocris, Ellisville, MO), and dihydrexidine (DHX) (a
gift from D. Nichols, Purdue University). Data was collected from
a minimum of three independent replicate experiments with each
sample measured in triplicate. Statistical analysis of data was
Figure 1. Drug discovery and development pipeline for new insecticidal chemistries. A: The illustration shows critical steps involved with
the ‘‘genome-to-lead’’ (described in this manuscript) and ‘‘lead-to-product’’ phases. Abbreviations: (EPA) Environmental Protection Agency; (FDA)
Food and Drug Administration; (SAR) structure-activity relationship study. The intended administration route of a particular chemistry dictates the
federal agency that will receive the registration package; B: Expanded details of the ‘‘hit-to-lead’’ phase including those pursued in this study.
doi:10.1371/journal.pntd.0001478.g001
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Inc., San Diego, CA).
Screening of AaDOP2 against the LOPAC1280 library
To identify novel AaDOP2 receptor antagonists, the Library of
PharmacologicallyActiveCompounds(LOPAC1280)wasscreenedat
the Integrated Screening Technologies Laboratory, Discovery Park,
Purdue University, using HEK-CRELuc-Aadop2 cells. These cells
were cultured as described above, expanded, and cryo-preserved, to
produce a uniform cell population. Briefly, cells (,2.5610
7)w e r e
harvested by non-enzymatic dissociation [0.5 mM EDTA in
Ca
2+Mg
2+free-phosphate buffered saline (CMF-PBS)] resuspended
in cell culture media, and pelleted by centrifugation for 5 min at
1006G. The pellet was resuspended in freezing media (Opti-MEM
supplemented with 10% DMSO and 20% FBS) to a concentration
of 5610
6/ml, frozen step-wise, and held in liquid N2 until use. Cells
were rapidly thawed, diluted in Opti-MEM, and 20 ml containing
25,000 cells were plated per well in 384-well plates (Nunc, Fisher
Scientific, Pittsburgh, PA) using a BiomekFX liquid handling station
(Beckman-Coulter, Brea, CA). The plates were incubated overnight
in a humidified incubator at 37uC and 5% CO2.
Prior to screen initiation, a ‘‘checkerboard’’ analysis was
conducted that included a minimum (300 nM dopamine in
combination with 10 mM SCH23390) and maximum (300 nM
dopamine) stimulatory condition. The data obtained were
analyzed to calculate the Z-factor [38] using a modified equation
that accounts for the number of replicates (NIH website: http://
assay.nih.gov/assay/index.php/Section2:Plate_Uniformity_and_
Signal_Variability_Assessment).
All compounds were diluted to appropriate concentrations and
suspended in assay buffer (Opti-MEM supplemented with 0.02%
ascorbic acid) using a BiomekFX 96-tip head. All LOPAC1280
compounds were screened in quadruplicate at a concentration of
10 mM, including duplicate samples on two separate assay plates in
different quadrants to control for plate and automation effects.
Each plate contained a dopamine response curve (14 nM–30 mM)
and antagonist control wells (10 mM SCH23390 in combination
with 300 nM dopamine). Following compound addition, dopa-
mine was added to each test well at a final concentration of
300 nM, and cells were incubated for 2 hr at 37uC in a humidified
incubator. The plates were then equilibrated at 25uC prior to the
addition of Steadylite plus luminescence reagent (PerkinElmer,
Shelton, CT). Plates were incubated on a shaker at 300 rpm for
5 min, and the luminescence signal was measured using a
DTX880 multimode reader (Beckman Coulter, Brea, CA) with a
1 sec integration time.
Raw screen data were processed as follows: the average
background luminescence (cells in the absence of dopamine or
LOPAC1280 compound) was subtracted from the raw data. Values
for the positive receptor activation control (300 nM dopamine)
were averaged within each assay plate and used to establish a
100% dopamine receptor stimulation level. Similarly, the average
response to SCH23390 was calculated within each assay plate to
establish a baseline inhibition for antagonist chemistries. The
average percent compound effect was calculated for each LOPAC
chemistry in comparison to the SCH23390 antagonist control.
The minimum criterion for selection of an antagonist ‘‘hit’’ was
established as the percent inhibition equivalent to that determined
for SCH23390+3 standard deviations.
‘‘Hit-to-lead’’ studies
Confirmation and secondary in vitro assays. Subsequent
validation assays using both the AaDOP2 and the human D1
dopamine receptor (hD1) [39] were conducted for select identified
‘‘hit’’ chemistries using a competitive binding cAMP accumulation
assay. In addition to SCH23390, these included amitriptyline
hydrochloride, doxepin hydrochloride, niclosamide, clozapine, (+)-
butaclamol hydrochloride, cis-(Z)-flupenthixol dihydrochloride,
resveratrol, mianserin hydrochloride (Sigma, St. Louis, MO),
piceatannol and methiothepin maleate (Tocris, Ellisville, MO).
The drugs were suspended from dimethyl sulfoxide (DMSO)
stocks in Hanks Balanced Salt Solution (HBSS) (HyClone, Logan,
UT) with with 0.1% fatty acid free bovine serum albumin (BSA)
and 20 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid
(HEPES), and serial dilutions were prepared using a Precision
2000 automated pipetting system (BioTek, Winooski, VT). The
cAMP accumulation assay was carried out as previously described
[36,37] with minor modifications to permit processing of a larger
number of samples in a semi-automated fashion. Briefly,
AaDOP2- or hD1-expressing cells were harvested using Hank’s
based non-enzymatic cell dissociation reagent (Invitrogen,
Carlsbad, CA), resuspended in Dulbecco’s modified eagle
medium (DMEM) (Invitrogen, Carlsbad, CA), centrifuged 5 min
at 1006 G, and resuspended in HBSS supplemented with 0.1%
BSA and 20 mM HEPES. Cells were seeded (50,000 cells in 40 ml)
in clear 96-well plates and incubated at 37uC with 5% CO2 for
1 hr. The cAMP accumulation assay was carried out in HBSS
supplemented with final concentrations of 0.1% BSA, 20 mM
HEPES, 0.5 mM 3-isobutyl-1-methylxanthine (IBMX), and
0.02% ascorbic acid in a final volume of 50 ml. The selected
compounds were added to the wells in duplicate, followed by
addition of dopamine (final concentration 3 mM for AaDOP2 and
100 nM for hD1). Plates were incubated at room temperature for
1 hr, and the assay was terminated by addition of 25 ml of 9% ice-
cold trichloroacetic acid (TCA). Cell lysates were incubated on ice
for at least 1 hr prior to quantifying cAMP accumulation as
previously described [36,37].
In vivo Ae. aegypti bioassays
Single dose-point and dose response in vivo mosquito bioassays
were used to assess the toxicity of selected AaDOP2 receptor
antagonists identified in the chemical screen. Larvae of Ae. aegypti
(Liverpool strain) were reared under standard laboratory conditions
on a 12 hr day/night cycle at 75% RH and 28uC, and bioassays
were conducted at room temperature (22–24uC). Larvae were
transferred from standard rearing trays into six-well tissue culture
plates(Corning, Inc. Corning,NY)usinga small plastic pipette. Ten
L4-stage larvae were included per well, each containing five ml of
de-ionized water and the assigned drug concentration. Controls
were conducted similarly but lacked a drug treatment. Bioassays
employed a double-blind experimental design, and percent
mortality was scored 24 hr following administration of drugs.
Single dose-point assays were conducted using 400 mMd r u ga n d
included three biological replicates each consisting of 50–100
larvae. Dose-response assays were conducted using five doses (400,
200, 100, 50, and 25 mM) of the compounds suspended in water,
with water alone as a control. Five technical replicates, each
including 10 larvae, were performed per dose, and the assay was
repeated three times. Statistical analyses included one sample t-tests
(single-point assays) and determination of the LC50 and LC90 values
(dose-response assays) conducted with GraphPad Prism 5 software
(GraphPad Software Inc., San Diego, CA).
Results
Molecular analyses
mRNA transcripts for Aadop1 and Aadop2 were detected by RT-
PCR in eggs, larvae, pupae, and adult male and female Ae. aegypti
D1-like Dopamine Receptors in Aedes aegypti
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splice junctions at each intron/exon boundary for both receptor
genes. Using a combination of evidence from our RT-PCR data,
the genome sequence, and related sequences in D. melanogaster,w e
predicted the gene structure and complete coding regions of
Aadop1 (Genbank accession: JN043502) and Aadop2 (Genbank
accession: JN043503) (Figure S2). A neighbor-joining sequence
analysis was conducted to assess the relationships of AaDOP1 and
AaDOP2 with other representative biogenic amine receptors
(Figure 2). AaDOP1 was included in a clade (bootstrap=100)
containing the presumably orthologous D1-like dopamine recep-
tors D-Dop1 of D. melanogaster [30,40], DOP1 of A. mellifera [41],
and Isdop1 of I. scapularis [36,42]. AaDOP2 clustered with two
presumably orthologous insect D1-like dopamine receptors
(INDRs) [43], DopR99B (DAMB) of D. melanogaster [31,44] and
DOP2 of A. mellifera [41], as well as Isdop2 of I. scapularis [36]. The
INDR-like and Isdop2 sequences were also joined together in a
larger clade (bootstrap=76) containing the octopamine receptors
OAMB of D. melanogaster [45] and OCT1 [46] of A. mellifera,
consistent with Mustard et al. [41]. The human D1-like dopamine
receptors formed a separate clade (bootstrap=100) distinct from
the arthropod dopamine receptors.
The deduced amino acid sequences of AaDOP1 and AaDOP2
were analyzed to identify conserved structural features typically
associated with biogenic amine-binding GPCRs (Table S2), as well
as unique regions that could be potentially exploited for
development of mosquito-specific chemistries. Conserved features
included sites predicted for ligand binding, protein stability, and G
protein-coupling, and residues with potential for post-translational
modification were identified. Alignments of the full-length
AaDOP1 and AaDOP2 amino acid sequences (Figure 3) indicated
that these sequences were divergent in the presumed N- and C-
termini and the intracellular and extracellular loops, and the TM
domains were moderately conserved (47% amino acid identity). A
substantial difference was observed in the composition and relative
size of the third intracellular loop that was much larger in
AaDOP2 (115 amino acids) than in AaDOP1 (62 amino acids).
Only a modest level of similarity was observed between the
mosquito and human D1-like dopamine receptors, which shared
between 47–54% amino acid identities among the TM domains,
which typically represent the most conserved regions of GPCRs
(Table S3). Moreover, comparison of the predicted TM domains
from multiple invertebrate and vertebrate D1-like dopamine
receptors showed that only 34% (58/172) of the amino acids
were shared among all species included in the alignment (Figure
S3). The highest level of sequence similarity to the TM domains of
AaDOP1 and AaDOP2 was found in their predicted D. melanogaster
orthologs, D-Dop1 (88% identity) (Table S3) and DopR99B (97%
identity), respectively.
Heterologous expression and pharmacological
characterization
To study the function of the putative dopamine receptors
AaDOP1 and AaDOP2, each receptor was expressed in HEK293
cells. Production of the mosquito receptor transcripts in transient-
ly-transfected cells was first verified using RT-PCR (Figure S4).
Increases of intracellular cAMP were detected in cells transiently
expressing either AaDOP1 [2.760.6 fold (n=3)] or AaDOP2
[48614 fold (n=3)] in response to a single dose of dopamine
(10 mM) (Figure S5). No significant increase in cAMP was
observed in the mock transfected cells (empty pcDNA3.1+ vector).
For cells transiently expressing AaDOP1, relatively high levels of
constitutive activity were observed (17.662.4 fold greater than in
mock transfected cells) as compared to AaDOP2 (1.8360.93 fold
greater than in mock transfected cells).
Subsequently, dose-response curves for seven different biogenic
amines were generated using HEK-CRELuc cells stably express-
ing either AaDOP1 or AaDOP2 (Figure 4; Table 1). Again,
dopamine stimulated both receptors, with EC50 values determined
at 3.161.1 nM and 240616.0 nM for AaDOP1 and AaDOP2,
respectively (Figure 4A–B; Table 1). In addition, we observed
activation of the AaDOP1 receptor by epinephrine
(EC50=5.861.5 nM) and norepinephrine (EC50=7606180 nM)
(Table 1). Conversely, no significant stimulation was observed for
the AaDOP2 receptor by epinephrine or norepinephrine (Table 1).
Neither receptor was stimulated by histamine, octopamine,
serotonin, or tyramine (EC50$10 uM). The effects of known
synthetic dopamine receptor agonists were also investigated
(Figure 4C–D; Table 1). Considerable stimulation was observed
for AaDOP1 with the agonists listed in their rank order of potency:
DHX.SKF81297.SKF38393. In contrast, of the synthetic
agonists tested here, only treatment with DHX resulted in
significant dose-dependent activation of AaDOP2. The addition
of the D1 dopamine receptor antagonist SCH23390 (10 mM)
robustly inhibited the dopamine-mediated stimulation of both
AaDOP1 and AaDOP2 (Figure 4E).
Screening of Aadop2 against the LOPAC1280 library
We selected the AaDOP2 receptor for an antagonist screen of
the LOPAC1280 library because of its low constitutive activity and
strong dopamine response compared to background (approxi-
mately 10-fold) (Figure 4B,D). Using dose-response studies, it was
determined that 300 nM dopamine alone and in combination with
10 mM SCH23390 created a suitable ‘‘signal window’’ for
identification of AaDOP2 antagonists (Figure 4F). A ‘‘checker-
board analysis’’ using these conditions and assuming four
replicates in the screen generated a Z-factor of 0.560.1 (n=3),
indicating that the assay was suitable for antagonist screening.
The criterion for ‘‘hit’’ detection was established relative to the
control antagonist (SCH23390 response +3 standard deviations),
such that only those compounds that inhibited the dopamine
response by at least 81% were considered (Table 2). Based on this,
our screen identified 51 potential antagonists of the AaDOP2
receptor (complete screen results provided in Table S4). These
compounds were partitioned into seven different classes based on
their known biochemical interactions with mammalian molecular
targets that included dopamine receptor antagonists (20), serotonin
(6), histamine (2), and acetylcholine receptor ligands (1), biogenic
amine uptake inhibitors (9), protein kinase modulators (6), and
miscellaneous chemistries such as cell cycle regulators and
apoptosis inhibitors (7).
Ten ‘‘hit’’ compounds (amitriptyline hydrochloride, (6)-buta-
clamol hydrochloride, clozapine, doxepin hydrochloride, cis-(Z)-
flupenthixol dihydrochloride, methiothepin maleate, mianserin
hydrochloride, niclosamide, piceatannol, and resveratrol), in
addition to SCH23390 were selected for screen validation assays.
These compounds were tested for their activity in cAMP
accumulation assays to control for potential ‘‘off-target’’ effects
(i.e. chemistries that affect the CRELuc reporter system). Seven of
these compounds were potent antagonists of the AaDOP2
receptor, as shown by the dose-dependent reduction of cAMP
accumulation relative to the dopamine-stimulated control (Table 3,
Figure 5). Three of the compounds (i.e. niclosamide, piceatannol,
and resveratrol) showed no significant antagonistic effects against
AaDOP2 in the cAMP accumulation experiments, having IC50
values $10 mM.
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The deduced amino acid sequences for the mosquito dopamine receptors AaDOP1 and AaDOP2 and additional receptors for dopamine, muscarinic
acetylcholine, octopamine, serotonin, and tyramine from Drosophila melanogaster and Apis mellifera, as well as the human D1-like and D2-like
dopamine receptors were aligned for use in the analysis. Bootstrap values (100 replicates) are indicated with numbers at supported branches. The
outgroup is a D. melanogaster diuretic hormone receptor, a Class B GPCR. Abbreviations: Aa=Ae. aegypti; Is=I. scapularis; Dm=D. melanogaster;
Am=A. mellifera; Hs=H. sapiens. Sequences: Isdop1, D1-like dopamine receptor (ISCW001496); Isdop2, D1-like dopamine receptor (ISCW008775);
DmD-Dop1, D1-like dopamine receptor (P41596); DmDAMB, D1-like dopamine receptor (DopR99B/DAMB: AAC47161), DmDD2R, D2-like dopamine
receptor (DD2R-606: AAN15955); DmDih, diuretic hormone 44 receptor 1 (NP_610960.1); DmmAChR, muscarinic acetylcholine receptor (AAA28676);
DmOAMB, octopamine receptor in mushroom bodies, isoform A (NP_732541); DM5HT1A, serotonin receptor 1A, isoform A (NP_476802); DmTyr,
tyramine receptor (CG7431: NP_650652); AmDOP1, D1-like dopamine receptor (dopamine receptor, D1, NP_001011595); AmDOP2, D1-like dopamine
receptor (dopamine receptor 2, NP_001011567), AmDOP3, D2-like dopamine receptor (AmDOP3, NP_001014983); AmmAChR, muscarinic
acetylcholine receptor (XP_395760); AmOA1, octopamine receptor (oar, NP_001011565); Am5HT1A, serotonin receptor (5ht-1, NP_001164579);
AmTyr, tyramine receptor (XP_394231); HsD1, D1-like dopamine receptor (D(1A), NP_000785); HsD2,D2-like dopamine receptor (D(2), NP_000786);
HsD3, D2-like dopamine receptor (D(3), NP_000787); HsD4, D2-like dopamine receptor (D(4), NP_000788); HsD5, D1-like dopamine receptor (D(1B)/D5,
NP_000789).
doi:10.1371/journal.pntd.0001478.g002
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Confirmation and secondary in vitro assays. Selected hit
compounds were also tested against the human D1 receptor (hD1)
to allow for comparisons of relative potency between species
(Table 3). These experiments clearly indicated a unique
pharmacology of AaDOP2 compared to hD1 with divergent rank
order functional potencies that showed no significant correlation
(R
2,0.15). For example, the prototypical mammalian D1 anta-
gonist, SCH23390 was greater than 3000-fold more selective for
hD1 than AaDOP2. In contrast, the data also revealed that two
structurally-related tricyclic antidepressants (i.e. amitriptyline and
doxepin) had more than 30-fold selectivity for AaDOP2 when
compared to hD1. These observations suggest that the significant
differences between these receptors could be exploited for the
development of AaDOP2-selective compounds.
In vivo Ae. aegypti bioassays
The toxicity of the AaDOP2 antagonist screen hits amitriptyline
and doxepin was assessed in Ae. aegypti larval bioassays. These
chemistries were selected due to their relatively higher potency at
AaDOP2 compared to hD1 (Table 3). Single dose-point assays at
400 mM effective concentration of drug revealed that amitriptyline
(93% average mortality) and doxepin (72% average mortality)
each caused significant mortality (p,0.05) 24 hours post-treatment
relative to the water control (0% mortality) (Figure 6A), whereas
no mortality was observed for SCH23390 during this timeframe
(data not shown). In addition, dose-response experiments were
conducted for amitriptyline, which caused a rapid and high
mortality effect in the single-point assays. The toxicity of
amitriptyline was dose-dependent, and the LC50 and LC90 values
were determined at 78 mM and 185 mM, respectively (Figure 6B).
Discussion
This work provides the first detailed investigation into the
molecular and pharmacological properties of D1-like dopamine
receptors, AaDOP1 and AaDOP2, from the mosquito vector of
dengue and yellow fever, Ae. aegypti, and the development of a cell-
based screen assay to discover antagonists of AaDOP2. Our study
employed a novel pipeline utilizing a ‘‘genome-to-lead’’ approach
for the discovery of new chemistries for vector control. This
research establishes a basis for improving understanding of
mosquito dopaminergic processes in vivo and for chemical
screening of these and other receptors characterized in arthropod
vectors of human disease, such as in the Lyme disease tick, I.
scapularis [36,42]. To our knowledge, Lee and Pietrantonio [47]
have published the only other study involving the functional
characterization of a biogenic amine-binding GPCR in mosqui-
Figure 3. Alignment of the complete Aedes aegypti AaDOP1 and AaDOP2 amino acid sequences. Highlighted areas designate residues
with shared biochemical characteristics, as designated by the ClustalW [33] output, where black shading=identical residues; dark shading=strongly
similar residues; light shading=weakly similar residues. Also noted are the residues composing the N- and C-termini and the transmembrane (TM)
domains I–VII.
doi:10.1371/journal.pntd.0001478.g003
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aegypti. Furthermore, ligands of only four other cloned GPCRs
have been pharmacologically verified in mosquitoes, including
those that target an adipokinetic hormone receptor, a corazonin
receptor, a crustacean cardioactive peptide receptor [48], and an
adipokinetic/corazonin-related peptide receptor in the malaria
mosquito, A. gambiae [49].
Typically, insects possess three different dopamine receptors
including two D1-like receptors and a single D2-like receptor [43].
Here, RT-PCR data were used to validate the two mosquito D1-
like dopamine receptor gene models [10]; this enabled confirma-
tion of intron/exon boundaries and prediction of the complete
protein coding regions needed prior to heterologous expression
studies. A putative D2-like dopamine receptor gene (AaDOP3) was
also identified in Ae. aegypti [10] although this receptor has not yet
been functionally characterized. The RT-PCR studies also
demonstrated that transcripts for both D1-like dopamine receptor
genes were detectable in each developmental stage of Ae. aegypti,
suggesting the importance of these receptors throughout the
mosquito life cycle. Much progress has been made in determining
the life-stage and tissue-specific expression dynamics of the
orthologous dopamine receptors in D. melanogaster [14,30,31,40,
44,50], A. mellifera [41,43,51,52,53,54], and most recently in the
Lyme disease tick, I. scapularis [42]. Our research will support
future complementary studies needed to localize expression of
these dopamine receptors in mosquito tissues to gain further
insight toward their neurophysiological roles.
The AaDOP1 and AaDOP2 amino acid sequences were
compared and analyzed to identify conserved as well as unique
features of the receptors. Several characteristics typically associ-
ated with biogenic amine-binding GPCRs were evident, including
aspartate residues in TM II and TM III that are thought to
interact with the amine moieties of catecholamines [55]. The
conserved serine residues in TM V and aromatic residues in TM
V and VI are also potentially important for ligand interaction
[56,57]. In both receptors, the conceptual cytoplasmic region of
TM III contained the conserved ‘‘DRY’’ motif associated with G
protein-coupling [58,59], and a pair of cysteine residues were
located in the extracellular loops I and II that may form a disulfide
bond for protein stabilization [58,60,61]. Interestingly, the
Figure 4. Pharmacological characterization of the Aedes aegypti AaDOP1 and AaDOP2 receptors. The mosquito receptors were stably
expressed in HEK 293-CRELuc cells for dose-response assays and determination of EC50 values (shown in Table 1). A, C: AaDOP1, B, D: AaDOP2.
Representative curves for A, B: biogenic amines; C, D: synthetic dopamine receptor agonists; E: Inhibitory effect of 10 mM SCH23390 in the presence
of 1 mM dopamine (n=4) shown for both mosquito dopamine receptors. ** p,0.01; *** p,0.001; F: Dose-response curve of dopamine for AaDOP2 in
the absence or presence of 10 mM SCH23390 used to identify an appropriate ‘‘signal window’’ for chemical library screening. The concentration of
dopamine selected for screening (300 nM) is indicated with a box. CPS=counts per second; M=molarity.
doi:10.1371/journal.pntd.0001478.g004
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long in AaDOP2 (115 amino acids) than in AaDOP1 (62 amino
acids), but the sizes of the carboxyl tail region were similar
between these receptors. This corresponded well with the relative
sizes of these features in the fruit fly and honeybee orthologs [43];
however, the significance of these characteristics is yet to be
determined in the mosquito. Importantly, the AaDOP1 and
AaDOP2 sequences were markedly different from the human D1-
like dopamine receptor sequences. Although a modest level of
amino acid identity (,50%) was observed between the TM
domains, the N- and C-termini and extracellular and intracellular
loop regions were highly divergent (data not shown). These
differences suggest that there exists potential for identifying
chemistries that are mosquito-specific and, importantly, do not
interfere with dopaminergic functioning in humans.
Heterologous expression experiments conducted in HEK293
cells provided experimental evidence that the Ae. aegypti receptors
are functional D1-like dopamine receptors. We measured
significant increases in cAMP accumulation following dopamine
treatment of cells transiently expressing either AaDOP1 or
AaDOP2, suggesting that both receptors couple to Gas proteins.
This effect was further substantiated in cell lines stably co-
expressing either of these receptors and the CRELuc reporter
system, as measured by an increase in luciferase activity following
dopamine treatment. Future research is needed to determine if
these receptors operate through multiple cellular signaling
mechanisms, such as was shown for the D. melanogaster dopamine
receptor involved with both cAMP and calcium signaling [62].
The stably transformed cell lines were used to compare the
pharmacological properties of AaDOP1 and AaDOP2 in response
to seven different biogenic amines. For dopamine, we measured
EC50 values in the nanomolar range for both AaDOP1
(3.161.1 nM) and AaDOP2 (240616 nM). However, there were
differences in the responses of these receptors to the other biogenic
amines. AaDOP2 was activated only with dopamine, whereas
AaDOP1 was stimulated by dopamine, epinephrine, and to a lesser
extent, norepinephrine. These results were similar to those
reported for the orthologous dopamine receptors in the tick I.
scapularis [36,42]. Another difference between AaDOP1 and
AaDOP2 was observed regarding constitutive activity. In both
transient and stable expression experiments, the AaDOP1 receptor
exhibited significant constitutive activity, as determined by the
elevated levels of cAMP detected in the absence of a receptor
agonist, whereas AaDOP2 did not. Such constitutive activity was
also reported for the D1-like dopamine receptors AmDOP1 of A.
mellifera [41], CeDOP1 from the nematode Caenorhabditis elegans
[63], Isdop1 of I. scapularis [36], and the human D5 receptor [64].
Seifert and Wenzel-Seifert [65] proposed that constitutive activity
of a GPCR may enable the maintenance of basal neuronal
activity, although evidence is needed to support such activity for
AaDOP1 in vivo.
The pharmacological properties of AaDOP1 and AaDOP2 were
further explored by testing their responses to synthetic dopamine
receptor agonists and antagonists. Both receptors were strongly
stimulated by the agonist DHX; however, only AaDOP1
significantly responded to the well characterized D1 agonists
SKF81297 and SKF38393. This differential response to the SKF
compounds was also observed for the orthologous D1-like
dopamine receptors in the tick I. scapularis [36]. Interestingly,
neither of the D. melanogaster D1-like dopamine receptors was
strongly stimulated by SKF38393 [31,40]. Both AaDOP1 and
AaDOP2 were inhibited by the antagonist SCH23390, as were the
tick D1-like receptors [36]. This contrasted with the lack of
significant inhibition reported by SCH23390 for D-dop1 in the
fruit fly [40] and DOP1 of the honeybee [51]. Given the limited
number of drugs that have been tested against these receptors, to
date, these differential pharmacological responses provide further
evidence that it may be possible to discover chemistries that
operate specifically at the mosquito dopamine receptors.
Our over-arching goal was to develop a pipeline to identify lead
chemistries active at biogenic-amine binding GPCRs in vector
arthropods. Broadly speaking, we define a lead chemistry as any
molecule, or its analog or derivative, with potential for insecticide
development. In our study, this refers to any molecule identified by
screening and subsequently confirmed in a variety of ‘‘hit-to-lead’’
assays. The LOPAC1280 library was chosen for our pilot screen
because it is enriched with chemistries that influence dopaminergic
processes and includes other GPCR-binding ligands. We hypoth-
esized that chemistries that antagonize these dopamine receptors
may possess insecticidal properties. Precedent for this concept
stems from pest management successes associated with the use of
phenylpyrazoles (e.g. Fipronil) and cyclodienes, which block
GABA-gated chloride channels and have highly insecticidal
properties [66,67]. This notion was pursued using HEK293 cells
stably expressing AaDOP2 because this receptor has a robust
response to dopamine and a low constitutive activity, which are
properties that aid interpretation of screen data. Our initial screen
was directed at the identification of AaDOP2 antagonists; the
success of this experiment justifies expanded screening to explore
the antagonist chemical ‘‘space’’, and with assay modification,
screens to detect agonists active at this receptor. Moreover,
development of the AaDOP1 assay would enable comparative
screens against LOPAC1280 chemistries.
Of the 51 hit AaDOP2 antagonists identified in the LOPAC1280
library, 20 (39%) are known antagonists of mammalian dopamine
receptors. A majority of these chemistries fall into the benzodi-
azepine, phenothiazine, or thioxanthene classes that in other
systems are known to bind other biogenic amine receptors.
Included were ligands selective for D1- and D2-like dopamine
receptors in mammalian systems, as well as several non-dopamine
receptor selective compounds such as (6)-butaclamol, cis-(Z)-
flupenthixol, and the atypical antipsychotic, clozapine. These
three compounds were tested in a dose-response format for their
Table 1. Responses of AaDOP1 and AaDOP2 to biogenic
amines and synthetic dopamine receptor agonists.
Compound EC50 values
AaDOP1 AaDOP2
Dopamine 3.161.1 nM 240616 nM
Epinephrine 5.861.5 nM $10 mM
Norepinephrine 7606180 nM $10 mM
Histamine $10 mM $10 mM
Octopamine $10 mM $10 mM
Serotonin $10 mM $10 mM
Tyramine $10 mM $10 mM
Dihydrexidine 6.961.5 nM 290654 nM
SKF 81297 2467.0 nM $10 mM
SKF 38393 310646 nM $10 mM
HEK293 cells stably expressing both a CRELuc reporter construct and either of
the receptors were stimulated with potential agonists. Dose-response curves
were plotted and the EC50 values were calculated. Compounds with EC50 values
$10 mM are considered to lack intrinsic activity at AaDOP2.
doi:10.1371/journal.pntd.0001478.t001
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AaDOP2 hit class Chemistry % of the SCH23390 effect
{ Mode of action
Dopamine receptor antagonists (20) R(+)-SCH-23390 hydrochloride*
{ 83 D1 DAR antagonist
(6)-Butaclamol hydrochloride 81 D2 DAR selective antagonist
(+)-Butaclamol hydrochloride
{ 87 DAR antagonist
Chlorprothixene hydrochloride 94 D2 DAR antagonist
Clozapine
{ 81 D4 DAR selective antagonist
Fluphenazine dihydrochloride 82 DAR antagonist
cis-(Z)-Flupenthixol dihydrochloride
{ 88 DAR antagonist
JL-18 98 D4 DAR selective antagonist
LE 300 99 D1 DAR antagonist
Loxapine succinate 97 N.D.
(6)-Octoclothepin maleate 97 D2DAR/5-HT receptor antagonist
Perphenazine 95 D2 DAR antagonist, s receptor
agonist
Prochlorperazine dimaleate 83 DAR antagonist
Promazine hydrochloride 88 D2 DAR antagonist
Propionylpromazine hydrochloride 85 D2 DAR antagonist
Risperidone 83 D2 DAR/5-HT receptor antagonist
Triflupromazine hydrochloride 88 D2 DAR antagonist
Trifluoperazine dihydrochloride 81 DAR/calmodulin antagonist
Thiothixene hydrochloride 86 DAR antagonist
Thioridazine hydrochloride 86 DAR/Ca
2+ channel antagonist
Serotonin receptor ligands (6) Amperozide hydrochloride 83 5-HT & DAR antagonist
LY-310,762 hydrochloride 81 5-HT1D selective antagonist
Mianserin hydrochloride
{ 95 5-HT receptor antagonist
Methiothepin mesylate
{ 99 5-HT1 selective antagonist
Pirenperone 90 5-HT2 selective antagonist
Ritanserin 83 5-HT2 selective antagonist
Histamine receptor ligands (2) Ketotifen fumarate 96 H1 antagonist
Promethazine hydrochloride 95 H1 antagonist
mAChR ligands (1) Benztropine mesylate 89 mAChR antagonist
Biogenic amine uptake inhibitors (9) Amitriptyline hydrochloride
{ 90 N.D.
Amoxapine 90 NOR uptake inhibitor
49-Chloro-3-alpha-(diphenylmethoxy) tropane
hydrochloride
85 DA uptake inhibitor
Doxepin hydrochloride
{ 90 N.D.
Imipramine hydrochloride 96 5-HT & NOR uptake inhibitor
Maprotiline hydrochloride 82 NOR uptake inhibitor
Nortriptyline hydrochloride 96 N.D.
Protriptyline hydrochloride 82 NOR uptake inhibitor
Trimipramine maleate 87 5-HT & NOR uptake inhibitor
Protein kinase modulators (6) Diacylglycerol kinase inhibitor I 90 Diacylglycerol kinase inhibitor
Kenpaullone 83 Phosphatase inhibitor
NSC 95397 83 Syk, Lck inhibitor
Piceatannol
{ 98 CDK inhibitor
Phorbol 12-myristate 13-acetate 88 Activates protein kinase C
Purvalanol A 93 CDK1, CDK2, CDK5 inhibitor
Miscellaneous; e.g., cell cycle regulators/
apoptosis modulators (7)
beta-Lapachone 86 Induces apoptosis
(S)-(+)-Camptothecin 93 DNA topoisomerase I inhibitor
Emetine dihydrochloride hydrate 86 Apoptosis inducer; RNA-protein
translation inhibitor
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IC50 values demonstrated the following rank order of potency
clozapine.cis-flupenthixol.butaclamol. The next largest group-
ing of identified compounds includes inhibitors of the biogenic
amine transporters (9 compounds, 18%). Several serotonin
receptor antagonists (6 compounds, 12%) were identified as well.
Follow-up dose response studies with selected chemistries from the
identified transport inhibitors and serotonin antagonists (i.e.
methiothepin, mianserin, amitriptyiline, and doxepin) revealed
that these compounds were potent antagonists at the AaDOP2
receptor and were much more potent than the prototypical D1
antagonist, SCH23390 (Table 3). The antagonistic activity of these
ligands is not completely surprising; the National Institute of
Mental Health’s Psychoactive Drug Screening Program (NIMH-
PDSP) database reports Ki values for the human D1-like dopamine
receptors at 80–900 nM (http://pdsp.med.unc.edu/). However,
these observations, combined with the dopamine antagonist screen
results, indicate that well studied and clinically used compounds
could be used to target invertebrate GPCRs. In fact, a number of
the chemistries identified in our screen have been used in humans
for decades, suggesting the possibility of ‘‘drug repurposing’’ as
insecticides. Further precedent for the concept of insect-specific
chemistries can be drawn from the fact that a number of
insecticides (e.g., pyrethroids and fipronil) are considerably more
selective at invertebrate as opposed to mammalian targets [68].
The screen also identified multiple protein kinase modulators and
several agents that regulate germane cellular functions that
presumably inhibit the CRE response via non-AaDOP2 mecha-
nisms. Support for this hypothesis was demonstrated in the direct
measurement of cAMP accumulation experiments, where resver-
atrol, pieacetannol, and niclosamide each lacked activity. The
remaining three ‘‘hit’’ compound classes included antagonists of
either histamine or muscarinic acetylcholine receptors, and this
likely reflects the lack of receptor selectivity for these ligands.
The LOPAC1280 library includes several known antagonists of
mammalian dopamine receptors that did not qualify as hits in our
screen. In part, this can be explained by the fact that we used a
highly stringent cut-off to signify antagonistic activity at AaDOP2.
Had we reduced the stringency to select for hits with an
antagonistic effect equivalent to that of SCH23390+6 standard
deviations (69% inhibition), our screen would have returned an
additional 13 hit chemistries, including compounds predicted to
AaDOP2 hit class Chemistry % of the SCH23390 effect
{ Mode of action
Idarubicin 83 Disrupts topoisomerase II
Mitoxantrone 83 DNA synthesis inhibitor
Niclosamide
{ 95 Uncouples oxidative
phosphorylation
Resveratrol
{ 89 Inhibits lipo- & cyclo-oxygenase
activity
Total 51 (4% hit rate)
{Percent inhibition of receptor response in the presence of test compound relative to the SCH23390 control;
*, SCH23390 ‘‘antagonist control’’;
{, compound analyzed in cAMP confirmation assay; CDK, cyclin dependent kinase; DAR, dopamine receptor; H, histamine receptor; Lck, lymphocyte-specific protein




Table 3. Confirmation and secondary assays for ‘‘hit’’ antagonists of AaDOP2 and human D1 receptor.
Compound
IC50 value (at 3 mM dopamine for
AaDOP2)
IC50 value (at 100 nM dopamine for
hD1)
Relative fold selectivity for
AaDOP2 vs. hD1
Amitriptyline 1463.4 nM 470649 nM 36
(+) Butaclamol 480633 nM 3.760.64 nM 0.008
cis-(Z)-Flupenthixol 2065.4 nM 1161.9 nM 0.55
Clozapine 3166.5 nM 300635 nM 9.7
Doxepin 3164.9 nM 960686 nM 31
Methiothepin 1465.1 nM 80611 nM 5.7
Mianserin 120640 nM 12006260 nM 10
Niclosamide $10 mM N.D. N.D.
Piceatannol $10 mM N.D. N.D.
Resveratrol $10 mM N.D. N.D.
SCH23390 1600673 nM 0.4760.03 nM 0.0003
Select chemistries and the assay control (SCH23390) were tested in dose-response cAMP assays in the presence of 3 mM dopamine in AaDOP2- or 100 nM dopamine in
hD1-expressing cells (Figure 5). Compounds with IC50 values $10 mM are considered to lack activity at AaDOP2 and were not tested at hD1. N.D.=not determined;
hD1=Human D1 dopamine receptor.
doi:10.1371/journal.pntd.0001478.t003
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accumulation assays were used for dose-response assays and determination of IC50 values for SCH23390 (antagonist control) and seven AaDOP2
antagonists (shown in Table 3) identified in the chemical library screen.
doi:10.1371/journal.pntd.0001478.g005
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more selective for D2-like dopamine receptors. Considering the
substantial divergence between the mosquito and human D1-like
dopamine receptor sequences, there is a strong possibility that a
subset of the ‘‘non-hit’’ dopamine receptor antagonists are not
active at the mosquito receptor. In support of this, the prototypical
mammalian D1 antagonist, SCH23390, was greater than 3000-
fold more selective for hD1 than AaDOP2. Although our
comparison data set is limited to only eight compounds, these
experiments suggest a very divergent pharmacology between these
human and mosquito dopamine receptors. Thus, our study
provides a foundation for subsequent comparative pharmacolog-
ical analyses of the mosquito and human dopamine receptors.
Analyses involving a small subset of compounds revealed a
correlation between our in vitro and in vivo data. The AaDOP2
antagonist screen hits, amitriptyline and doxepin, caused signifi-
cant lethality in the mosquito bioassay. Our finding that these
drugs each have a relatively higher potency at the mosquito
dopamine receptor than at the human dopamine receptor (hD1)
has implications for the identification of arthropod-selective
chemistries. Drugs with minimal or no impact on the neurological
functioning of humans or other vertebrate species are particularly
desirable as prospects for insecticide development. Conversely,
SCH23390, which is active at AaDOP2 only in the micromolar
range and was several fold more selective for hD1 in cAMP assays,
did not cause significant mortality at 24 hr.
The success of this initial chemical library screen in identifying
new mosquitocidal chemical leads justifies the pursuit of an
expanded high-throughput screening effort involving thousands or
hundreds of thousands of chemistries against mosquito dopamine
receptors. Our platform is also amenable for the screening of
agonist chemistries active at these mosquito dopamine receptors,
as well as for Gas-coupled biogenic amine targets of other vector
arthropods, and also could be modified to screen Gai/o-coupled
receptors [69]. Importantly, the identification of lead AaDOP2
receptor antagonistic chemistries provides a basis for investigating
the effect of these or related compounds on mosquito dopaminer-
gic processes in vivo [70]. Follow-up research is needed to
determine the precise mechanism(s) of amitriptyline- and doxe-
pin-induced mortality in Ae. aegypti. Further work is also needed to
determine if these chemistries and associated derivatives or analogs
identified by chemical screens possess the properties desired of an
insecticide (e.g. bioavailability, in vivo potency/toxicity, suitable
half-life, lack of effects on non-target organisms, suitability for
synthesis and formulation). Molecular modeling of three dimen-
sional GPCR structures and their binding capabilities, as reported
for an adipokinetic hormone receptor in A. gambiae [71] and a
tyramine receptor in the moth Plodia interpunctella [72], may
facilitate in silico chemical screening [73] and ligand-receptor
studies that permit the design or refinement of lead molecules
active at mosquito GPCRs.
Historically, multiple neuroactive processes in arthropods have
been exploited for pest control using insecticides such as
chlorinated hydrocarbons, organophosphates, methylcarbamates,
pyrethroids, amidines, and phenylpyrazoles [67]. Resistance
involving each of these classes (the vast majority of which operate
by affecting ion channels and neurotransmitters) has been
documented. The development of new mode-of-action insecticides
could improve our arsenal against mosquito populations that have
developed resistance to existing chemical formulations [1]. We
suggest that the two dopamine receptors characterized here, as
well as other biogenic amine-binding GPCRs [74,75], represent
promising targets for new insecticide research, due to their
presumably central roles in insect neurobiology. This ‘‘proof-of-
concept’’ study sets the stage for target-specific approaches for
vector control. Such efforts, in parallel with activities of
organizations such as the Innovative Vector Control Consortium,
may help to realize the goal of delivering new insecticides for
reduction of vector-borne diseases [2].
Supporting Information
Figure S1 Gel electrophoresis for non-quantitative RT-
PCR of Aedes aegypti Aadop1 and Aadop2.A : Aadop1
amplified with primers Aadop_1F/1R (224 bp amplicon), B:
Aadop2 amplified with primers Aadop2_Full_F/R (1,425 bp
amplicon). Transcripts were detected for both dopamine receptors
in each developmental stage of the mosquito and both adult sexes.
As expected, no amplification products were detected in the
negative control, which contained identical reagents as the other
reactions but lacked an RNA template. Abbreviations: (M) DNA
size marker (HyperLadder I, Bioline USA Inc., Randolph, MA);
(E) egg; (L) larva; (P) pupa; (AF) adult female; (AM) adult male; (C)
negative control.
(TIF)
Figure S2 Gene models for Aedes aegypti Aadop1 and
Aadop2.A : Aadop1, B: Aadop2. Exons (E) are shown with gray
bars, and introns with solid black lines. Numbers above the box/
Figure 6. Toxicity of antagonist screen hits in Ae. aegypti larval bioassays. A: Ae. aegypti larval bioassay showing toxicity of amitriptyline and
doxepin at a single dose point (400 mM) compared to the water control; Ami=amitriptyline, Dox=Doxepin; * indicates p,0.05; B: Ae. aegypti larval
bioassay involving amitriptyline in a dose-response format (25 mM–400 mM).
doi:10.1371/journal.pntd.0001478.g006
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The putative transmembrane domains (I–VII) are shown with
black boxes along the exons. The gene structures of Aadop1 and
Aadop2 include three and two introns, respectively, which is
consistent with other characterized insect dopamine receptor
genes that also contain introns [43], but is in contrast with the
single exon gene structures reported for the two D1-like receptor
genes in humans [39,76] and the Lyme disease tick, I. scapularis
[36]. The genomic supercontigs on which Aadop1 and Aadop2
reside have not yet been linked to chromosomal positions [10], so
their relative genome organization cannot yet be compared with
other insects. However, in A. gambiae the predicted orthologs of
Aadop1 and Aadop2 are positioned on chromosome 2R
(GPRDOP1: AGAP004613) and the X chromosome (GPRDOP2:
AGAP000667) [9].
(TIF)
Figure S3 Alignment of transmembrane domains of
Aedes aegypti AaDOP1 and AaDOP2 and other D1-like
receptors. Aligned receptor amino acid sequences include each
of the two D1-like receptors reported in Drosophila melanogaster (D-
Dop1; DopR99B/DAMB) [30,31,40,44], Apis mellifera (AmDOP1;
AmDOP2) [41], Ixodes scapularis (Isdop1; Isdop2) [36,42], and Homo
sapiens (HsD1, HsD5) [39,76]. Amino acids included in the
alignment were related to the TM regions predicted for D.
melanogaster [30,31]. Shaded amino acids designate residues
conserved among each of the aligned TM domain sequences.
(TIF)
Figure S4 Expression of Aedes aegypti Aadop1 and
Aadop2 in transiently-transfected HEK 293 cells. Gel
electrophoresis shows PCR and RT-PCR amplification of Aedes
aegypti A: Aadop1and B: Aadop2 using primers Aadop1_1F/2R
(amplicon=1058 bp) and Aadop2_FullF/FullR (1425 bp), respec-
tively. Abbreviations: (M) DNA size marker (HyperLadder I,
Bioline USA Inc., Randolph, MA); lanes under the heading
‘‘PCR’’ include controls for DNA contamination in the RNA
preparation: (2) no DNA template; (+) A: DNA construct
pcDNA3.1+/Aadop1 and B: DNA construct pcDNA3.1+/Aadop2;
(V) mRNA from cells transfected with empty vector pcDNA3.1;
(C) mRNA from cells transfected with construct A: pcDNA3.1+/
Aadop1 and B: pcDNA3.1+/Aadop2. Lanes under the heading
‘‘RT-PCR’’ show mRNA transcript detection experiments; (2)n o
template mRNA; (+) mRNA from adult female Ae. aegypti (non-
specific amplification products were eliminated with gel purifica-
tion); (V) mRNA from cells transfected with empty vector
pcDNA3.1; (C) mRNA from cells transfected with construct A:
pcDNA3.1+/Aadop1 and B: pcDNA3.1+/Aadop2.
(TIF)
Figure S5 Response of AaDOP1 and AaDOP2 following
dopamine treatment in transiently-transfected HEK
cells. Significant responses to dopamine were observed for both
AaDOP1 and AaDOP2, relative to basal conditions (p,0.05).
(TIF)
Table S1 Primer pairs and experimental conditions
used in RT-PCR analysis of Aadop1 and Aadop2
transcripts.
(DOC)
Table S2 Summary of selected amino acid features of
Aedes aegypti AaDOP1 and AaDOP2.
(DOC)
Table S3 Comparison of transmembrane domains of A.
aegypti AaDOP1 and AaDOP2 and related D1-like
receptors.
(DOC)
Table S4 Results of the Aedes aegypti AaDOP2 antago-
nist screen of the LOPAC1280 library.
(PDF)
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